市場調査レポート
商品コード
1063913

双極性障害(2030年まで):世界の医薬品予測および市場分析

Bipolar Disorder - Global Drug Forecast and Market Analysis to 2030

出版日: | 発行: GlobalData | ページ情報: 英文 138 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
双極性障害(2030年まで):世界の医薬品予測および市場分析
出版日: 2022年02月07日
発行: GlobalData
ページ情報: 英文 138 Pages
納期: 即納可能 即納可能とは
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

双極性障害の市場規模は、2020年から2030年にかけて緩やかな成長が予想されます。双極性障害の市場は、多くの承認済み治療薬が存在し、その多くが安価なジェネリック医薬品として販売されているため、競争が激しくなっています。当市場では予測期間中に7つの後期パイプライン医薬品が上市されると予測され、8MMの市場成長の主な原動力になると予想されます。また、Intra-Cellular Therapies社のCaplytaが2030年に8億ドルの売上高を上げ、双極性障害市場で最も売れる医薬品になると予想されます。

当レポートでは双極性障害の世界市場を調査し、市場の概要、主要な促進要因、阻害要因、課題、COVID-19の影響、2020年から2030年までの双極性障害治療薬市場の年間収益、患者あたりの治療費、3つの患者セグメント(双極性I型、双極性II型、サイクロサイミック障害)における治療使用パターンの予測、競合情勢など、体系的な情報を提供しています。

目次

目次

第1章 双極性障害:エグゼクティブサマリー

  • 2020年から2030年まで双極性障害市場で予想される適度な成長
  • 非定型抗精神病薬が支配的な市場では、新しい作用機序が双極性障害の重要な研究開発戦略である
  • 双極性障害市場で満たされていないアンメットニーズ製品の機会が残っている
  • 新規の後期パイプライン薬が成長の主要な促進力となる
  • 医師の洞察

第2章 イントロダクション

  • 触媒
  • 関連レポート
  • 今後のレポート

第3章 病気の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
  • 分類
  • 予後

第4章 疫学

  • 病気の背景
  • 危険因子と併存疾患
  • 世界的および歴史的動向
  • 予測調査手法
    • ソース
    • 予測の前提条件と方法
    • 予測の前提条件と方法:双極性障害の12か月および生涯の一般的症例
  • 双極性障害の疫学予測(2020年~2030年)
    • 双極I型障害の12か月の総流行症例
    • 双極I型障害の年齢別の12か月の総流行症例
    • 双極I型障害の性別特有の12か月の総流行症例
    • 双極I型障害の生涯の総流行症例
    • 双極I型障害の年齢別の生涯の総流行症例
    • 双極I型障害の性別の生涯の総流行症例
    • 双極II型障害の12か月の総流行症例
    • 双極II型障害の年齢別の12か月の総流行症例
    • 双極II型障害の性別特有の12か月の総流行症例
    • 双極II型障害の生涯の総流行症例
    • 双極II型障害の年齢別の生涯の総流行症例
    • 双極II型障害の性別の生涯の総流行症例
    • 気分循環性障害の12か月の総流行症例
    • 気分循環性障害の年齢別の12か月の総流行症例
    • 気分循環性障害の性別特有の12か月の総流行症例
    • 気分循環性障害の生涯の総流行症例
    • 気分循環性障害の年齢別の生涯の総流行症例
    • 気分循環性障害の性別の生涯の総流行症例
  • 討論
    • 疫学予測インサイト
    • COVID-19の影響
    • 分析の限界
    • 分析の強み

第5章 疾病管理

  • 診断と治療の概要
  • 疾病管理に関する追加のKOL洞察

第6章 競合情勢評価

  • 概要

第7章 アンメットニーズと機会の評価

  • 概要
  • 双極性うつ病の効果的な治療オプション
  • EPSと代謝変化のリスクが低い抗精神病薬
  • 安全性プロファイルが改善された気分安定薬
  • 診断率を向上させるための医師への教育
  • 双極性障害のために特別に開発された新薬

第8章 研究開発戦略

  • 概要
    • ラベルの拡張
    • 新しい作用機序
    • 再処方
  • 臨床試験デザイン
    • エンドポイント
    • 包含/除外基準
    • 試用期間

第9章 パイプライン評価

  • 概要
  • 臨床開発における有望な医薬品

第10章 パイプライン評価分析

  • 概要
  • 競争力のある評価
    • 双極性うつ病
    • 双極性マニア
    • 双極性障害に関連する激越

第11章 現在および将来のプレーヤー

  • 概要
  • 取引動向

第12章 市場の見通し

第13章 付録

図表

List of Tables

List of Tables

  • Table 1: Bipolar Disorder: Key Metrics in the 8MM
  • Table 2: Symptom Criteria for Manic, Hypomanic and Major Depressive Episodes
  • Table 3: DSM-V Classification of Bipolar Disorder
  • Table 4: Risk Factors and Comorbid Conditions Associated with Bipolar Disorder
  • Table 5: Treatment Guidelines for Bipolar Disorder
  • Table 6: Bipolar Disorder Market - Global Drivers and Barriers, 2020-2030
  • Table 7: Key Events Impacting Sales for Bipolar Disorder in the US, 2020-2030
  • Table 8: Bipolar Disorder Market - Drivers and Barriers in the US, 2020-2030
  • Table 9: Key Events Impacting Sales for Bipolar Disorder in the 5EU, 2020-2030
  • Table 10: Bipolar Disorder Market - Drivers and Barriers in the 5EU, 2020-2030
  • Table 11: Key Events Impacting Sales for Bipolar Disorder in Japan, 2020-2030
  • Table 12: Bipolar Disorder Market - Drivers and Barriers in Japan, 2020-2030
  • Table 13: Key Events Impacting Sales for Bipolar Disorder in Canada, 2020-2030
  • Table 14: Bipolar Disorder Market - Drivers and Barriers in Canada, 2020-2030
  • Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for Bipolar Disorder in 2020 and 2030
  • Figure 2: Analysis of the Company Portfolio Gap in Bipolar Disorder During the Forecast Period
  • Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs for Bipolar Depression Benchmarked Against the Standard of Care, Generic Lithium
  • Figure 4: Competitive Assessment of the Marketed and Pipeline Drugs for Bipolar Mania Benchmarked Against the Standard of Care, Generic Lithium
  • Figure 5: Competitive Assessment of the Marketed and Pipeline Drugs for Agitation Associated with Bipolar Disorder Benchmarked Against the Standard of Care, Generic Haloperidol
  • Figure 6: The Etiology and Pathophysiology of Bipolar Disorder
  • Figure 7: 8MM, 12-Month and Lifetime Total Prevalence of Bipolar Spectrum Disorder, Men and Women (%), Ages ≥13 Years, 2020
  • Figure 8: 8MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of Bipolar I Disorder
  • Figure 9: 8MM, Sources Used and Not Used to Forecast the Lifetime Total Prevalent Cases of Bipolar I Disorder
  • Figure 10: 8MM, Sources Used to Forecast the 12-Month Total Prevalence of Bipolar II Disorder
  • Figure 11: 8MM, Sources Used to Forecast the Lifetime Total Prevalent Cases of Bipolar II Disorder
  • Figure 12: 8MM, Sources Used to Forecast the 12-Month Total Prevalence of Cyclothymic Disorder
  • Figure 13: 8MM, Sources Used to Forecast the Lifetime Total Prevalence of Cyclothymic Disorder
  • Figure 14: 8MM, 12-Month Total Prevalent Cases of Bipolar I Disorder, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 15: 8MM, 12-Month Total Prevalent Cases of Bipolar I Disorder by Age, N, Both Sexes, 2020
  • Figure 16: 8MM, 12-Month Total Prevalent Cases of Bipolar I Disorder by Sex, N, Ages ≥18 Years, 2020
  • Figure 17: 8MM, Lifetime Total Prevalent Cases of Bipolar I Disorder, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 18: 8MM, Lifetime Total Prevalent Cases of Bipolar I Disorder by Age, N, Both Sexes, 2020
  • Figure 19: 8MM, Lifetime Total Prevalent Cases of Bipolar I Disorder by Sex, N, Ages ≥18 Years, 2020
  • Figure 20: 8MM, 12-Month Total Prevalent Cases of Bipolar II Disorder, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 21: 8MM, 12-Month Total Prevalent Cases of Bipolar II Disorder by Age, N, Both Sexes, 2020
  • Figure 22: 8MM, 12-Month Total Prevalent Cases of Bipolar II Disorder by Sex, N, Ages ≥18 Years, 2020
  • Figure 23: 8MM, Lifetime Total Prevalent Cases of Bipolar II Disorder, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 24: 8MM, Lifetime Total Prevalent Cases of Bipolar II Disorder by Age, N, Both Sexes, 2020
  • Figure 25: 8MM, Lifetime Total Prevalent Cases of Bipolar II Disorder by Sex, N, Ages ≥18 Years, 2020
  • Figure 26: 8MM, 12-Month Total Prevalent Cases of Cyclothymic Disorder, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 27: 8MM, 12-Month Total Prevalent Cases of Cyclothymic Disorder by Age, N, Both Sexes, 2020
  • Figure 28: 8MM, 12-Month Total Prevalent Cases of Cyclothymic Disorder by Sex, N, Ages ≥18 Years, 2020
  • Figure 29: 8MM, Lifetime Total Prevalent Cases of Cyclothymic Disorder, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 30: 8MM, Lifetime Total Prevalent Cases of Cyclothymic Disorder by Age, N, Both Sexes, 2020
  • Figure 31: 8MM, Lifetime Total Prevalent Cases of Cyclothymic Disorder by Sex, N, Ages ≥18 Years, 2020
  • Figure 32: Unmet Needs and Opportunities in Bipolar Disorder
  • Figure 33: Overview of the Development Pipeline in Bipolar Disorder
  • Figure 34: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for Bipolar Disorder in the 8MM During the Forecast Period
  • Figure 35: Competitive Assessment of the Marketed and Pipeline Drugs for Bipolar Depression Benchmarked Against the SOC, Generic Lithium
  • Figure 36: Competitive Assessment of the Marketed and Pipeline Drugs for Bipolar Mania Benchmarked Against the SOC, Generic Lithium
  • Figure 37: Competitive Assessment of the Marketed and Pipeline Drugs for Agitation Associated with Bipolar Disorder Benchmarked Against the SOC, Generic Haloperidol
  • Figure 38: Analysis of the Company Portfolio Gap in Bipolar Disorder During the Forecast Period
  • Figure 39: Global (8MM) Sales Forecast by Country for Bipolar Disorder in 2020 and 2030
  • Figure 40: Global (8MM) Sales Forecast by Class for Bipolar Disorder in 2020 and 2030
  • Figure 41: Sales Forecast by Class for Bipolar Disorder in the US in 2020 and 2030
  • Figure 42: Sales Forecast by Class for Bipolar Disorder in the 5EU in 2020 and 2030
  • Figure 43: Sales Forecast by Class for Bipolar Disorder in Japan in 2020 and 2030
  • Figure 44: Sales Forecast by Class for Bipolar Disorder in Canada in 2020 and 2030
目次
Product Code: GDHC234PIDR

Bipolar disorder, known originally as manic-depressive illness, is a mental disorder characterized by periods of mania and depression. Manic episodes are the distinguishing feature of this condition and consist of an abnormally elevated, expansive, or irritable mood, as well as persistently increased activity or energy. Conversely, phases of depression involve significantly depressed mood and loss of interest or pleasure. The frequency, severity, and pattern of these episodes can vary considerably over time and among individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage.

The bipolar disorder market is competitive and crowded with a multitude of approved therapies, many of which are available as inexpensive generics. The approved drugs in the bipolar disorder market can be divided into two broad categories: mood stabilizers and antipsychotics. Lithium is widely considered to be the gold standard for bipolar disorder based on its efficacy as a maintenance treatment and its ability to treat acute episodes of both mania and depression.

Key Highlights

  • Moderate growth is expected in the bipolar disorder market from 2020 to 2030.
  • GlobalData anticipates that seven late stage pipeline drugs will launch over the forecast period. These are expected to be the main driver of growth in the bipolar disorder market across the 8MM.
  • GlobalData expects Intra-Cellular Therapies' Caplyta to become the top-selling drug in the bipolar disorder market with sales of $800M in 2030.
  • The current key players in the bipolar disorder market are those that market atypical antipsychotic products. However, many products have lost market exclusivity or are facing imminent patent expiry. As such, many of the respective companies are expected to lose their positions in this market over the forecast period due to generic competition.
  • Opportunities remain for pharmaceutical companies to develop drugs with improved safety profiles, as well as novel drugs developed specifically for bipolar disorder.

Key Questions Answered

  • What are the key bipolar disorder treatments in 2020?
  • When will the late stage pipeline products launch, and how will it affect drug sales and the overall bipolar disorder market in the 8MM?
  • Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

  • Overview of bipolar disorder, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized bipolar disorder therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments ( bipolar I, bipolar II and cyclothymic disorder) forecast from 2020 to 2030.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the bipolar disorder therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bipolar disorder therapy. The most promising candidates in Phase III and IIb development are profiled.
  • Analysis of the current and future market competition in the global bipolar disorder therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global bipolar disorder therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bipolar disorder therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Bipolar Disorder: Executive Summary

  • 1.1 Modest Growth Expected in the Bipolar Disorder Market from 2020-2030
  • 1.2 In a Market Dominated by Atypical Antipsychotics, Novel Mechanisms of Action Are a Key R&D Strategy for Bipolar Disorder
  • 1.3 Opportunities Remain for Products that Will Fulfill Unmet Needs in the Bipolar Disorder Market
  • 1.4 Novel Late-Stage Pipeline Drugs Will Be a Key Driver of Growth
  • 1.5 What Do Physicians Think?

2 Introduction

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Disease Overview

  • 3.1 Etiology and Pathophysiology
    • 3.1.1 Etiology
    • 3.1.2 Pathophysiology
  • 3.2 Classification
  • 3.3 Prognosis

4 Epidemiology

  • 4.1 Disease Background
  • 4.2 Risk Factors and Comorbidities
  • 4.3 Global and Historical Trends
  • 4.4 Forecast Methodology
    • 4.4.1 Sources
    • 4.4.2 Forecast Assumptions and Methods
    • 4.4.3 Forecast Assumptions and Methods: 12-Month and Lifetime Prevalent Cases of Bipolar Disorder
  • 4.5 Epidemiological Forecast for Bipolar Disorder (2020-2030)
    • 4.5.1 12-Month Total Prevalent Cases of Bipolar I Disorder
    • 4.5.2 Age-Specific 12-Month Total Prevalent Cases of Bipolar I Disorder
    • 4.5.3 Sex-Specific 12-Month Total Prevalent Cases of Bipolar I Disorder
    • 4.5.4 Lifetime Total Prevalent Cases of Bipolar I Disorder
    • 4.5.5 Age-Specific Lifetime Total Prevalent Cases of Bipolar I Disorder
    • 4.5.6 Sex-Specific Lifetime Total Prevalent Cases of Bipolar I Disorder
    • 4.5.7 12-Month Total Prevalent Cases of Bipolar II Disorder
    • 4.5.8 Age-Specific 12-Month Total Prevalent Cases of Bipolar II Disorder
    • 4.5.9 Sex-Specific 12-Month Total Prevalent Cases of Bipolar II Disorder
    • 4.5.10 Lifetime Total Prevalent Cases of Bipolar II Disorder
    • 4.5.11 Age-Specific Lifetime Total Prevalent Cases of Bipolar II Disorder
    • 4.5.12 Sex-Specific Lifetime Total Prevalent Cases of Bipolar II Disorder
    • 4.5.13 12-Month Total Prevalent Cases of Cyclothymic Disorder
    • 4.5.14 Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder
    • 4.5.15 Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder
    • 4.5.16 Lifetime Total Prevalent Cases of Cyclothymic Disorder
    • 4.5.17 Age-Specific Lifetime Total Prevalent Cases of Cyclothymic Disorder
    • 4.5.18 Sex-Specific Lifetime Total Prevalent Cases of Cyclothymic Disorder
  • 4.6 Discussion
    • 4.6.1 Epidemiological Forecast Insight
    • 4.6.2 COVID-19 Impact
    • 4.6.3 Limitations of the Analysis
    • 4.6.4 Strengths of the Analysis

5 Disease Management

  • 5.1 Diagnosis and Treatment Overview
  • 5.2 Additional KOL Insights on Disease Management

6 Competitive Assessment

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Effective Treatment Options for Bipolar Depression
  • 7.3 Antipsychotics With a Low Risk of EPS and Metabolic Changes
  • 7.4 Mood Stabilizers With Improved Safety Profiles
  • 7.5 Education for Physicians in Order to Improve Diagnosis Rates
  • 7.6 Novel Drugs Developed Specifically for Bipolar Disorder

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Label Expansion
    • 8.1.2 Novel Mechanisms of Action
    • 8.1.3 Reformulations
  • 8.2 Clinical Trials Design
    • 8.2.1 Endpoints
    • 8.2.2 Inclusion/Exclusion Criteria
    • 8.2.3 Trial Duration

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

  • 10.1 Overview
  • 10.2 Competitive Assessment
    • 10.2.1 Bipolar Depression
    • 10.2.2 Bipolar Mania
    • 10.2.3 Agitation Associated With Bipolar Disorder

11 Current and Future Players

  • 11.1 Overview
  • 11.2 Deal-Making Trends

12 Market Outlook

13 Appendix